Suscribirse

Determinants of retinopathy progression in type 1 diabetes mellitus - 08/09/11

Doi : 10.1016/S0002-9343(99)00165-5 
Robert A Cohen, MD a, Charles H Hennekens, MD, DrPH a, William G Christen a : ScD, Andrzej Krolewski, MD, PhD b, David M Nathan, MD c, Michael J Peterson, PhD d, Frances LaMotte, BS a, JoAnn E Manson, MD, DrPH a,
a Department of Medicine (RAC, CHH, WGC, FL, JEM), Division of Preventive Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA 
b Section on Epidemiology and Genetics (AK), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA 
c Diabetes Unit (DMN), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA 
d Research Department (MJP), Pfizer Pharmaceuticals, Groton, Connecticut, USA 

*Requests for reprints should be addressed to JoAnn E. Manson, MD, Division of Preventive Medicine at Brigham and Women’s Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts 02215-1204

Abstract

PURPOSE: To determine the risk factors for retinopathy progression in type 1 (insulin-dependent) diabetes mellitus in a prospective cohort study.

SUBJECTS AND METHODS: Subjects were 485 participants in the Sorbinil Retinopathy Trial, a randomized trial of aldose reductase inhibition among patients aged 18 to 56 years with type 1 diabetes mellitus (duration of 1 to 15 years) and no or only mild retinopathy. Retinopathy progression, assessed by seven-field stereoscopic fundus photography, was defined as worsening by two or more levels on a standardized grading scale at the end of follow-up (median, 41 months).

RESULTS: The relative risks for retinopathy progression according to successively greater quintiles of total glycosylated hemoglobin level at baseline, after adjusting for age, diabetes duration, sorbinil assignment, and other variables, were 1.0, 2.0, 1.6, 3.7, and 4.4 (P trend <0.0001). Risk increased with greater baseline diastolic blood pressure: 1.0 for <70 mm Hg, 1.2 for 70 to 79 mm Hg, and 1.8 for ≥80 mm Hg (P for trend = 0.04). Diastolic blood pressure was a significant risk factor for progression in participants with mild baseline retinopathy (P for trend <0.02) but not in those without retinopathy at entry. Systolic blood pressure, by comparison, was not associated with progression. Baseline total cholesterol level was a marginally significant predictor of retinopathy progression when examined as a categorical variable (relative risks for increasing quartiles; 1.0, 1.6, 1.8, 1.9; P for trend = 0.03) but not when it was examined as a continuous variable or when hypercholesterolemic patients were compared with those with normal levels. Furthermore, when cholesterol levels were updated in subsequent visits, it was not a significant predictor of progression, and low density lipoprotein (LDL) cholesterol levels did not predict progression no matter how analyzed. Smoking was not associated with progression of retinopathy.

CONCLUSIONS: Levels of hyperglycemia and diastolic blood pressure predicted progression of retinopathy in type 1 diabetes mellitus. We found only a suggestion of an association between total cholesterol level (but not of LDL cholesterol level) and progression of retinopathy; resolution of this issue will require additional studies with larger sample sizes and longer follow-up.

El texto completo de este artículo está disponible en PDF.

Esquema


 The Sorbinil Retinopathy Trial was funded by the National Eye Institute, Grant Number EY10624, and Pfizer, Inc.


© 1999  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 107 - N° 1

P. 45-51 - juillet 1999 Regresar al número
Artículo precedente Artículo precedente
  • Does a year make a difference? changes in physician satisfaction and perception in an increasingly capitated environment
  • Eric S Nadler, Suzanne Sims, Patrick H Tyrance, David G Fairchild, Troyen A Brennan, David W Bates
| Artículo siguiente Artículo siguiente
  • Evidence-based organ allocation
  • Stefanos A Zenios, Lawrence M Wein, Glenn M Chertow

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.